louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03731923: Abbreviated MRI for HCC Surveillance
Official title: MR Value: Clinical Feasibility of Abbreviated MR Protocol for HCC Surveillance in High-risk Group
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Hepatocellular Carcinoma
Liver Cirrhosis
Chronic Hepatitis
Keywords: MRI
ultrasonography
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Guerbet
First posted: 2018-11-06
Enrollment: 257
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study aims to investigate the clinical feasibility of abbreviated liver MRI for HCC surveillance in a high-risk group.


Eligibility criteria: Inclusion Criteria:

* high risk of HCC development (chronic hepatitis B, chronic hepatitis C, liver cirrhosis)
* no history of HCC
* on surveillance of HCC using ultrasonography
* sign informed consent

Exclusion Criteria:

* history of HCC
* congestive hepatopathy
* iron deposition
* any absolute or relative contra-indication of contrast-enhanced MRI

Primary outcomes:
measure: Sensitivity for detecting HCC
timeFrame: 12 months after last MRI
Secondary outcomes:
measure: Table time of abbreviated MRI
timeFrame: 1 day after each MRI
measure: In-room time of abbreviated MRI
timeFrame: 1 day after each MRI
measure: Specificity for detecting HCC
timeFrame: 12 months after last MRI
measure: Sensitivity for detecting early stage HCC
timeFrame: 12 months after last MRI
measure: Specificity for detecting early stage HCC
timeFrame: 12 months after last MRI
measure: Image quality of abbreviated liver MRI
timeFrame: 12 months after last MRI
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea, Seoul St. Mary's Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jeong Min Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04160923: Incidence and Neonatal Outcome of Eclamptic Parturient in Tertiary Hospital.
Official title: Incidence and Neonatal Outcome of Eclamptic Parturient : a 13-years Retrospective Study From a Single Tertiary Care Center Anesthetic Aspect.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Eclampsia
Lead sponsor: Siriraj Hospital
Sponsor class: OTHER
First posted: 2019-11-13
Enrollment: 46
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient who diagnosed with eclampsia during January2005-December 2017

Brief summary: Eclampsia is a rare but serious disease that can happen during the pregnancy. Both general and regional anesthesia can both be performed in eclamptic patients. Eclamptic patients has greater risk if undergo general anesthesia such as risks associated with general anesthesia in pregnancy and also cerebral hemorrhage risks from hypertension during laryngoscope application and thrombocytopenia that can happen in eclamptic patients. So, most of Anesthesiologists tend to avoid performing general anesthesia in these patients. But spinal anesthesia also has side effects such as hypotension or epidural hematoma. And nowadays there's minimal evidence on suitable anesthesia in eclamptic patients. Our study wants to review on how choice of anesthesia affects these patients both mothers and their neonates


Eligibility criteria: Inclusion Criteria:

* Patient who diagnosed with eclampsia.

Exclusion Criteria:

* Incomplete medical record.

Primary outcomes:
measure: The incidence of eclampsia in Siriraj Hospital.
timeFrame: 13 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok Noi
country: Thailand
facility: Department of Anesthesiology, Siriraj Hospital, Mahidol University
state: Bangkok
city: Bangkok Noi
country: Thailand
facility: Pattrapun Wongsripuemtet
state: Bangkok
Study officials:
affiliation: Department of Anesthesiology, Siriraj Hospital, Mahidol University
name: Soawaphak Chumpathong, Assoc. Prof.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01358123: Value of Von Willebrand Factor in Portal Hypertension
Official title: Von Willebrand Factor As Non-Invasive Predictor Of Clinically Significant Portal Hypertension And Mortality In Patients With Liver Cirrhosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Liver Cirrhosis
Portal Hypertension
Keywords: liver cirrhosis
portal hypertension
survival
von willebrand factor
hepatic venous pressure gradient
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2011-05-23
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 98
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with liver cirrhosis of all etioloiges, routinely scheduled for routine HVPG measurement will systematically be included during the study period

Brief summary: In patients with liver cirrhosis elevated levels of von Willebrand factor antigen (vWF-Ag) are found frequently but the clinical significance is unclear. vWF-Ag plays an important role in primary haemostasis and development of thrombotic vascular obliteration is discussed as a possible mechanism leading to portal hypertension. Invasive measurement of hepatic venous pressure gradient (HVPG) is the current gold standard for the diagnosis of portal hypertension. The investigators hypothesize that vWF-Ag levels in plasma may correlate with portal pressure and predict clinically significant portal hypertension (CSPH, HVPG \>=10mmHg) and its complications.

Detailed description: Patients with alcoholic, viral (chronic hepatitis C), and cryptogenic liver cirrhosis are included. Portal hemodynamics are assessed by HVPG measurement, vWF-Ag levels were measured by ELISA. Results will be compared. 3 and 6 months mortality will be recorded.

Eligibility criteria: Inclusion Criteria:

* Liver cirrhosis

Exclusion Criteria:

* no HVPG measurement

Primary outcomes:
measure: von Willebrand Factor Ag Level
timeFrame: at first visit (HVPG Measurement) (day 1)
Secondary outcomes:
measure: Overall Mortality
timeFrame: 3 Months
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
affiliation: Medical University of Vienna
name: Arnulf Ferlitsch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05633238: SSVEP and Distractor Processing During Visual Search
Official title: SSVEP and Distractor Processing During Visual Search in Healthy Adults
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Healthy
Keywords: attention
visual search
Lead sponsor: Lehigh University
Sponsor class: OTHER
First posted: 2022-12-01
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: All participants receive each level of visual information (target or distractor)
Primary purpose: BASIC_SCIENCE

Brief summary: In this line of research, the researchers are utilizing an EEG measure of repeated visual stimulation, the Steady-State Visually Evoked Potential (SSVEP) to examine processing of target and distractor information during visual search. This is a basic science study.

Detailed description: The researchers are interested in how the brain responds to target and distractor information during visual search. The researchers will manipulate the information available to the research participants, and measure research participants brain responses to information matching target or distractor features utilizing an EEG measure of repeated visual stimulation, the Steady-State Visually Evoked Potential (SSVEP).

Eligibility criteria: Inclusion Criteria:

* normal or corrected to normal visual acuity, normal color vision

Exclusion Criteria:

* history of neurological disorders

Primary outcomes:
measure: Steady-State Visually Evoked Response (SSVEP)
timeFrame: One day (during testing)
measure: Button Press Reaction Time
timeFrame: One day (during testing)
measure: Button Press Accuracy
timeFrame: One day (during testing)
Secondary outcomes:
Other outcomes:
Locations:
city: Bethlehem
country: United States
facility: Lehigh University
state: Pennsylvania
Study officials:
affiliation: Lehigh University
name: Nancy Carlisle, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01990638: Effects of Exercise Therapy on Ventricular and Endothelial Function in Patients After Coronary Artery Bypass Surgery
Official title: Effects of Exercise Therapy on Ventricular and Endothelial Function in Patients After Coronary Artery Bypass Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Type 2
Keywords: coronary artery bypass graft
Diabetes mellitus, type 2
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2013-11-21
Enrollment: 51
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients after coronary artery bypass surgery

Brief summary: The purpose of this study was (1) to compare the peak exercise capacity and left ventricular diastolic function between patients with and without diabetes and (2) to investigate the interrelation among peak oxygen consumption, left ventricular diastolic function, blood sugar, and lipid profile.


Eligibility criteria: Inclusion Criteria:

* well-controlled diabetes
* no history of myocardial infarction
* stable post coronary artery bypass surgery for at least 3 months

Exclusion Criteria:

* heart failure,
* valvular disease,
* abnormal kidney or liver function,
* cerebrovascular disease,
* primary pulmonary disease,
* other systemic or acute illness that may impede the testing or training

Primary outcomes:
measure: left ventricular diastolic function
timeFrame: 1 week
Secondary outcomes:
measure: flow-mediated dilation
timeFrame: 1 week
measure: exercise capacity
timeFrame: 1 week
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Ying-Tai Wu, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05647538: Bilateral Uterine Artery Ligation After Intrapartum or Postpartum Hemorrhage on Ovarian Reserve Markers and Pregnancy Outcome
Official title: The Effect of Bilateral Uterine Artery Ligation After Intrapartum or Postpartum Hemorrhage on Ovarian Reserve Markers and Pregnancy Outcome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bilateral Uterine Artery Ligation
Intrapartum or Postpartum Hemorrhage
Ovarian Reserve Markers
Pregnancy Outcome
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2022-12-12
Enrollment: 120
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients will be classified into two equal groups control group: underwent normal cesarean section without Postpartum hemorrhage, case group: cases underwent bilateral uterine artery ligation after Postpartum hemorrhage or intrapartum hemorrhage after cesarean section.

All patients will be subjected to the following clinical parameters assessment (age, cycle history, body mass index, parity, preceding treatment and/or surgery menstruation characteristics (quantity of menstruation and dysmenorrhoea) and endometrial biopsy.

Brief summary: The aim of this study is to assess the possible negative effects of uterine artery ligation on ovarian reserve markers and subsequent pregnancy outcomes

Detailed description: One of the most common surgical methods for preserving fertility is uterine artery ligation. It is simple to do and effective at reducing Postpartum hemorrhage after delivery . Additionally, it is rather safe and permits future childbearing for the patients.

Eligibility criteria: Inclusion Criteria:

* 120 females aged from 20 to 35 years old
* with Postpartum hemorrhage or intrapartum hemorrhage after cesarean section
* did not respond to medical therapy
* performed successful bilateral uterine artery ligation for hemorrhage management.

Exclusion Criteria:

* The presence of male factor or tubal factor.
* Hypertension, autoimmune disease, morbid obesity, absence of lactation diabetes millets, vascular disease, smoking or the use of alcohol.
* The presence of additional surgery or medical disease.
* Detection of a uterine anomaly, history of intrauterine growth restriction in previous pregnancies.
* Usage of a hormonal therapy through the research.

Primary outcomes:
measure: Ovarian reserve by anti-mullerian hormone
timeFrame: 24 months after bilateral uterine artery ligation.
Secondary outcomes:
measure: Ovarian reserve by follicle stimulating hormone
timeFrame: 24 months after bilateral uterine artery ligation.
measure: Ovarian reserve by antral follicle counts
timeFrame: 24 months after bilateral uterine artery ligation.
measure: Percent of subsequent pregnancy cases
timeFrame: 24 months after bilateral uterine artery ligation.
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Ahmed M.E. Ossman
Study officials:
References:
Clinical trial NCT00993538: Leukemia Cell Cultures for Research of New Anti-Cancer Therapies
Official title: Leukemia Cell Cultures for Research of New Anti-cancer Therapies
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Leukaemia
Keywords: Leukaemia
Blood and marrow cells culture
Cell growth
Cell differentiation
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2009-10-12
Enrollment: 180
Sex: ALL
Minimum age (years): 28
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The main objective of this project is not only a better understanding of the human leukemic disease but also to find new anti-leukemic or improve existing ones. This study has, the following aims:

* To analyze the genetic and epigenetic regulation of the retinoic acid induced cascade which leads to the expression of TRAIL in blood cells of patients with acute leukemia. This study will be complemented by the analysis of global gene expression (DNA chips) and of the DNA methylation state, and by chromatin immunoprecipitation experiences.
* To determine the efficiency of inhibitors of enzymes responsible for the modification of chromatin (existing and new developments within the European consortium EPITRON coordinated by Dr Gronemeyer) as inducers of differentiation and / or apoptosis of leukemic blasts.
* To explore Ikaros genic and functional abnormalities (genomic deletions, mutations, abnormal transcripts and proteins) in acute leukemia. The aim is to determine if these abnormalities may play a prognosis role.


Eligibility criteria: Inclusion Criteria:

* Patients with suspected de novo or secondary or relapsed acute leukemia, requiring complementary blood test and bone marrow analysis
* Patients older or equal than 28 days
* Informed consent signed

Exclusion Criteria:

* Pregnancy
* Breastfeeding

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service d'Hématologie et d'Oncologie
city: Strasbourg
country: France
facility: Service de Pédiaterie - Hôpital de Hautepierre
Study officials:
affiliation: Département d'Hématologie et d'Oncologie-hôpital de Hautepierre Strasbourg, France
name: Raoul Herbrecht, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01067638: The Effect of Tranexamic Acid on Postoperative Blood Loss and Coagulation in Patients With Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft; Double Blind Randomized Control Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Occlusive Disease
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2010-02-11
Enrollment: 90
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The Effect of Tranexamic Acid on Postoperative Blood loss and Coagulation in Patients with Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft; double blind randomized control study.


Eligibility criteria: Inclusion Criteria:

* Fifty patients undergoing OPCAB with preoperative hematocrit levels lower than 35%

Exclusion Criteria:

Patient who has

* Open heart surgery history before
* Thrombosis history
* Myocardial infarction (MI) within 7days recently
* Liver or Kidney disease
* been scheduled emergency surgery

Primary outcomes:
measure: Tranexamic acid significantly reduce the amount and incidence of homologous transfusion in anemic patients undergoing off-pump coronary artery bypass (OPCAB)
timeFrame: Check the amount 3 times before sugery and 24 hours after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei Univ.
Study officials:
References:
Clinical trial NCT05677438: A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
Official title: A Phase 2, Randomized, Double-blind, Multi-center, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-498 in Female Patients With Androgenetic Alopecia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Androgenetic Alopecia
Keywords: Androgenetic Alopecia
CKD-498
Lead sponsor: Chong Kun Dang Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2023-01-10
Enrollment: 121
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 54
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia

Detailed description: Participants were randomly assigned in a 1:1:1:1 ratio to the following group: 3 dose of CKD-498 and Placebo. The patients are prescribed oral administration of the appropriate IP daily (3 tablets: actual medication and placebo) for 24 weeks.

Eligibility criteria: Key Inclusion Criteria:

* Female of age 19-54 years
* Clinical Diagnosis of Androgenetic Alopecia
* Written informed consent

Key Exclusion Criteria:

* Other types of Alopecia or other diseases that can cause hair loss
* Clinically significant scalp disease such as seborrheic dermatitis or psoriasis
* Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator
* Women who are pregnant or breastfeeding
* Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of study drug

Primary outcomes:
measure: Total number of hair Changes
timeFrame: Baseline, Week 24
Secondary outcomes:
Other outcomes:
Locations:
city: Gyeonggi-do
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
Study officials:
affiliation: Seoul National University Bundang Hospital
name: ChangHun Huh, MD, PhD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02885038: Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies
Official title: Analyse de l'Effet Des caractéristiques de concentrés Plaquettaires Sur le Rendement Transfusionnel Chez Les Patients Ayant Une hémopathie Maligne et bénéficiant de Transfusions Plaquettaires à Titre Prophylactique
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lymphoma
Multiple Myeloma
Lymphocytic Leukemia
Hodgkin Disease
Keywords: Platelet Transfusion
Lead sponsor: Etablissement Français du Sang
Sponsor class: OTHER
Collaborators: name: Centre Hospitalier Universitaire de Besancon
First posted: 2016-08-31
Enrollment: 1101
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients with hematologic malignancies treated at the university hospital of Besançon who received at least one prophylactic platelet transfusion

Brief summary: Platelet concentrates (PCs) characteristics, such as storage duration, ABO compatibility, dose and source, may have an impact on transfusion responses and outcomes. Because of the relative scarcity of PCs the selection of a specific PC for issue to the patient remains a challenging process. Regulatory agencies do not fully address these characteristics in their recommendations for prophylactic transfusions.

The aim of the study was to analyse the effect of product-related factors in a real life setting, in order to determine which ones are the most relevant when selecting PCs for patients in prophylactic conditions. Two different endpoints are studied: the corrected count increment and the platelet transfusion time intervals.


Eligibility criteria: Inclusion Criteria:

* Inpatients in the hematology department between January 2001 and December 2012
* Hematologic malignancy
* At least one platelet transfusion (with platelet count ≤ 25 G/L)
* Age 18 and over at time of first transfusion

Exclusion Criteria:

* More than one hematologic malignancy
* Non-malignant haematological disorder

Primary outcomes:
measure: Corrected count increment
timeFrame: 24 hours post transfusion
Secondary outcomes:
measure: Transfusion interval
timeFrame: 7 days
Other outcomes:
Locations:
Study officials:
affiliation: Etablissement Français du Sang
name: Laurent BARDIAUX, MD
role: PRINCIPAL_INVESTIGATOR
References: